Proteomics in pancreatic cancer research

Proteomics

Volumn 11, Issue 4, 2011, Pages 816-828

  Cecconi, Daniela ^a   Palmieri, Marta ^a   Donadelli, Massimo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Biomarker; Biomedicine; Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; CYTOSKELETON PROTEIN;

BODY FLUID; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER INVASION; CANCER RESEARCH; CANCER RESISTANCE; CARCINOGENESIS; CELL HYPOXIA; DISTANT METASTASIS; HUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS JUICE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEOMICS; REVIEW; TISSUE CULTURE; TUMOR MICROENVIRONMENT;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; MICE; PANCREATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79551484371     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000401     Document Type: Review

References (89)

1. Li, J., Wientjes, M. G., Au, J. L., Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J. 12, 223-232.
2. Zamo, A., Cecconi, D., Proteomic analysis of lymphoid and haematopoietic neoplasms: there's more than biomarker discovery. J. Proteomics 2010, 73, 508-520.
3. Kelly, K. A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S. et al., Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008, 5, e85.
4. Sonnenberg, A., Liem, R. K., Plakins in development and disease. Exp. Cell Res. 2007, 313, 2189-2203.
5. Scarlett, C. J., Smith, R. C., Saxby, A., Nielsen, A. et al., Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology 2006, 130, 1670-1678.
6. Chen, R., Pan, S., Aebersold, R., Brentnall, T. A., Proteomics studies of pancreatic cancer. Proteomics Clin. Appl. 2007, 1, 1582-1591.
7. Ni, X. G., Zhou, L., Wang, G. Q., Liu, S. M. et al., The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol. Med. 2008, 14, 582-589.
8. Sun, H. Q., Yamamoto, M., Mejillano, M., Yin, H. L., Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem. 1999, 274, 33179-33182.
9. Thompson, C. C., Ashcroft, F. J., Patel, S., Saraga, G. et al., Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007, 56, 95-106.
10. Qi, T., Han, J., Cui, Y., Zong, M. et al., Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. J. Clin. Pathol. 2008, 61, 49-58.
11. Tomaino, B., Cappello, P., Capello, M., Fredolini, C. et al., Autoantibody signature in human ductal pancreatic adenocarcinoma. J. Proteome Res. 2007, 6, 4025-4031.
12. Yamaguchi, H., Lorenz, M., Kempiak, S., Sarmiento, C. et al., Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J. Cell Biol. 2005, 168, 441-452.
13. Paramio, J. M., Segrelles, C., Ruiz, S., Jorcano, J. L., Inhibition of protein kinase B (PKB) and PKCzeta mediates keratin K10-induced cell cycle arrest. Mol. Cell. Biol. 2001, 21, 7449-7459.
14. Laurent, A., Nicco, C., Chereau, C., Goulvestre, C. et al., Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005, 65, 948-956.
15. Tang, X., Tian, Z., Chueh, P. J., Chen, S. et al., Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface. Biochemistry 2007, 46, 12337-12346.
16. Morre, D. J., Hostetler, B., Weston, N., Kim, C., Morre, D. M., Cancer type-specific tNOX isoforms: a putative family of redox protein splice variants with cancer diagnostic and prognostic potential. Biofactors 2009, 34, 201-207.
17. Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A. et al., Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 919-922.
18. Duffy, J. P., Eibl, G., Reber, H. A., Hines, O. J., Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer 2003, 2, 12.
19. Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A. et al., Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001, 61, 6548-6554.
20. Simon, M. C., Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Adv. Exp. Med. Biol. 2006, 588, 165-170.
21. Welsh, S. J., Koh, M. Y., Powis, G., The hypoxic inducible stress response as a target for cancer drug discovery. Semin. Oncol. 2006, 33, 486-497.
22. Cui, Y., Zhang, D., Jia, Q., Li, T. et al., Proteomic and tissue array profiling identifies elevated hypoxia-regulated proteins in pancreatic ductal adenocarcinoma. Cancer Invest. 2009, 27, 747-755.
23. Seyfried, T. N., Shelton, L. M., Cancer as a metabolic disease. Nutr. Metab. (Lond) 2010, 7, 7.
24. Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M. et al., Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 2007, 30, 849-855.
25. Sheikh, A. A., Vimalachandran, D., Thompson, C. C., Jenkins, R. E. et al., The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 2007, 7, 1929-1940.
26. Manitz, M. P., Horst, B., Seeliger, S., Strey, A. et al., Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 2003, 23, 1034-1043.
27. Vogl, T., Ludwig, S., Goebeler, M., Strey, A. et al., MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004, 104, 4260-4268.
28. Koide, N., Yamada, T., Shibata, R., Mori, T. et al., Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin. Cancer Res. 2006, 12, 2419-2426.
29. Hibi, T., Mori, T., Fukuma, M., Yamazaki, K. et al., Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin. Cancer Res. 2009, 15, 2864-2871.
30. Zhu, Z., Friess, H., diMola, F. F., Zimmermann, A. et al., Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J. Clin. Oncol. 1999, 17, 2419-2428.
31. Cui, Y., Wu, J., Zong, M., Song, G. et al., Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int. J. Cancer 2009, 124, 1614-1621.
32. Kobayashi, H., Sagara, J., Kurita, H., Morifuji, M. et al., Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin. Cancer Res. 2004, 10, 572-580.
33. Kahsai, A. W., Zhu, S., Wardrop, D. J., Lane, W. S., Fenteany, G., Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. Chem. Biol. 2006, 13, 973-983.
34. Perez-Gonzalez, A., Rodriguez, A., Huarte, M., Salanueva, I. J., Nieto, A., hCLE/CGI-99, a human protein that interacts with the influenza virus polymerase, is a mRNA transcription modulator. J. Mol. Biol. 2006, 362, 887-900.
35. Hwang, T. L., Liang, Y., Chien, K. Y., Yu, J. S., Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006, 6, 2259-2272.
36. Patwa, T. H., Li, C., Poisson, L. M., Kim, H. Y. et al., The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis 2009, 30, 2215-2226.
37. Bloomston, M., Zhou, J. X., Rosemurgy, A. S., Frankel, W. et al., Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006, 66, 2592-2599.
38. Sun, Z. L., Zhu, Y., Wang, F. Q., Chen, R. et al., Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim. Biophys. Acta 2007, 1774, 764-771.
39. Guo, J., Wang, W., Liao, P., Lou, W. et al., Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009, 100, 2292-2301.
40. Fiedler, G. M., Leichtle, A. B., Kase, J., Baumann, S. et al., Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin. Cancer Res. 2009, 15, 3812-3819.
41. Zhao, J., Simeone, D. M., Heidt, D., Anderson, M. A., Lubman, D. M., Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J. Proteome Res. 2006, 5, 1792-1802.
42. Zhao, J., Qiu, W., Simeone, D. M., Lubman, D. M., N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J. Proteome Res. 2007, 6, 1126-1138.
43. Ono, M., Matsubara, J., Honda, K., Sakuma, T. et al., Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. J. Biol. Chem. 2009, 284, 29041-29049.
44. Yan, L., Tonack, S., Smith, R., Dodd, S. et al., Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J. Proteome Res. 2009, 8, 142-148.
45. Ingvarsson, J., Wingren, C., Carlsson, A., Ellmark, P. et al., Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008, 8, 2211-2219.
46. Faca, V. M., Song, K. S., Wang, H., Zhang, Q. et al., A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008, 5, e123.
47. Scheele, G. A., Two-dimensional gel analysis of soluble proteins. Charaterization of guinea pig exocrine pancreatic proteins. J. Biol. Chem. 1975, 250, 5375-5385.
48. Rosty, C., Christa, L., Kuzdzal, S., Baldwin, W. M. et al., Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002, 62, 1868-1875.
49. Gronborg, M., Bunkenborg, J., Kristiansen, T. Z., Jensen, O. N. et al., Comprehensive proteomic analysis of human pancreatic juice. J. Proteome Res. 2004, 3, 1042-1055.
50. Chen, R., Pan, S., Yi, E. C., Donohoe, S. et al., Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006, 6, 3871-3879.
51. Chen, R., Pan, S., Cooke, K., Moyes, K. W. et al., Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007, 34, 70-79.
52. Zhou, L., Lu, Z., Yang, A., Deng, R. et al., Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 2007, 7, 1345-1355.
53. Tian, M., Cui, Y. Z., Song, G. H., Zong, M. J. et al., Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8, 241.
54. Hurt, E. M., Thomas, S. B., Peng, B., Farrar, W. L., Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. Br. J. Cancer 2007, 97, 1116-1123.
55. Andre, S., Sanchez-Ruderisch, H., Nakagawa, H., Buchholz, M. et al., Tumor suppressor p16INK4a - modulator of glycomic profile and galectin-1 expression to increase susceptibility to carbohydrate-dependent induction of anoikis in pancreatic carcinoma cells. FEBS J. 2007, 274, 3233-3256.
56. Liu, C., Chen, Y., Yu, X., Jin, C. et al., Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference. BMC Cancer 2008, 8, 121.
57. Roda, O., Chiva, C., Espuna, G., Gabius, H. J. et al., A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells. Proteomics 2006, 6, S36-S41.
58. Antwi, K., Hanavan, P. D., Myers, C. E., Ruiz, Y. W. et al., Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines. Mol. Immunol. 2009, 46, 2931-2937.
59. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5, 157-171.
60. Okuyama, N., Ide, Y., Nakano, M., Nakagawa, T. et al., Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 2006, 118, 2803-2808.
61. Song, G., Cui, Y., Zhong, N., Han, J., Proteomic characterisation of pancreatic islet beta-cells stimulated with pancreatic carcinoma cell conditioned medium. J. Clin. Pathol. 2009, 62, 802-807.
62. Lee, H. S., Jeong, J., Lee, K. J., Characterization of vesicles secreted from insulinoma NIT-1 cells. J. Proteome Res. 2009, 8, 2851-2862.
63. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K. et al., Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 2007, 31, 1345-1350.
64. Harsha, H. C., Jimeno, A., Molina, H., Mihalas, A. B. et al., Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J. Proteome Res. 2008, 7, 4651-4658.
65. Thalappilly, S., Suliman, M., Gayet, O., Soubeyran, P. et al., Identification of multi-SH3 domain-containing protein interactome in pancreatic cancer: a yeast two-hybrid approach. Proteomics 2008, 8, 3071-3081.
66. Bauer, L., Venz, S., Junker, H., Brandt, R., Radons, J., Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1. Int. J. Oncol. 2009, 35, 97-107.
67. Suss, C., Czupalla, C., Winter, C., Pursche, T. et al., Rapid changes of mRNA-binding protein levels following glucose and 3-isobutyl-1-methylxanthine stimulation of insulinoma INS-1 cells. Mol. Cell. Proteomics 2009, 8, 393-408.
68. Cecconi, D., Scarpa, A., Donadelli, M., Palmieri, M. et al., Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis 2003, 24, 1871-1878.
69. Cecconi, D., Donadelli, M., Scarpa, A., Milli, A. et al., Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J. Proteome Res. 2005, 4, 1909-1916.
70. Cecconi, D., Donadelli, M., Rinalducci, S., Zolla, L. et al., Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007, 7, 1644-1653.
71. Cecconi, D., Donadelli, M., Dalla Pozza, E., Rinalducci, S. et al., Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. Proteomics 2009, 9, 1952-1966.
72. Song, D., Chaerkady, R., Tan, A. C., Garcia-Garcia, E. et al., Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 3275-3284.
73. Zhang, H., Cao, R., Lee, W. N., Deng, C. et al., Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J. Proteome Res. 9, 980-989.
74. Shekouh, A. R., Thompson, C. C., Prime, W., Campbell, F. et al., Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics 2003, 3, 1988-2001.
75. Grantzdorffer, I., Carl-McGrath, S., Ebert, M. P., Rocken, C., Proteomics of pancreatic cancer. Pancreas 2008, 36, 329-336.
76. Cheung, W., Darfler, M. M., Alvarez, H., Hood, B. L. et al., Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008, 8, 608-616.
77. Jessani, N., Niessen, S., Wei, B. Q., Nicolau, M. et al., A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2005, 2, 691-697.
78. Shields, D. J., Niessen, S., Murphy, E. A., Mielgo, A. et al., RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc. Natl. Acad. Sci. USA 107, 2189-2194.
79. Sitek, B., Sipos, B., Kloppel, G., Schmiegel, W. et al., Application of fluorescence dye saturation labeling for differential proteome analysis of 1, 000 microdissected cells from pancreatic ductal adenocarcinoma precursor lesions. Methods Mol. Biol. 2008, 425, 1-14.
80. Chen, G., Luo, Y., Wang, X., Zhao, Z. et al., A relatively simple and economical protocol for proteomic analyses of human 20S proteasome: compatible with both scaled-up and scaled-down purifications. Electrophoresis 2009, 30, 2422-2430.
81. Grote, T., Siwak, D. R., Fritsche, H. A., Joy, C. et al., Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008, 8, 3051-3060.
82. Alhamdani, M. S., Schroder, C., Werner, J., Giese, N. et al., Single-step procedure for the isolation of proteins at near-native conditions from mammalian tissue for proteomic analysis on antibody microarrays. J. Proteome Res. 9, 963-971.
83. Zhao, Y., Lee, W. N., Lim, S., Go, V. L. et al., Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells. Anal. Chem. 2009, 81, 764-771.
84. Xiao, J., Lee, W. N., Zhao, Y., Cao, R. et al., Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media. Pancreas 39, e17-e23.
85. Tonack, S., Aspinall-O'Dea, M., Jenkins, R. E., Elliot, V. et al., A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J. Proteomics 2009, 73, 352-356.
86. Ono, M., Shitashige, M., Honda, K., Isobe, T. et al., Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol. Cell. Proteomics 2006, 5, 1338-1347.
87. Taylor, S. W., Andon, N. L., Bilakovics, J. M., Lowe, C. et al., Efficient high-throughput discovery of large peptidic hormones and biomarkers. J. Proteome Res. 2006, 5, 1776-1784.
88. Findeisen, P., Peccerella, T., Post, S., Wenz, F., Neumaier, M., Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool. Rapid Commun. Mass Spectrom. 2008, 22, 1223-1229.
89. Ge, G., Wong, G. W., Classification of premalignant pancreatic cancer mass-spectrometry data using decision tree ensembles. BMC Bioinformatics 2008, 9, 275.